Methylated DLX4 Predicts Response to Pathologic Stage I Non-Small Cell Lung Cancer Resection

Methylated DLX4 is a potential biomarker that predicts poor prognosis after curative resection of pathologic stage I NSCLC. Identification of patients with methylated DLX4 may assist stratification for appropriate adjuvant treatment strategies.